Skip to main content

Osteonecrosis of the Jaw

0
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Oregon Therapeutics
Oregon TherapeuticsFrance - Paris
1 program
CONDOR Study of Osteonecrosis of the Jaws (TMJ)N/A1 trial
Active Trials
NCT01130389Completed309Est. Sep 2008
Amgen
AmgenTHOUSAND OAKS, CA
1 program
Osteonecrosis of the Jaw (ONJ) Case RegistryN/A1 trial
Active Trials
NCT01666106Completed327Est. Dec 2020

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
AmgenOsteonecrosis of the Jaw (ONJ) Case Registry
Oregon TherapeuticsCONDOR Study of Osteonecrosis of the Jaws (TMJ)

Clinical Trials (2)

Total enrollment: 636 patients across 2 trials

NCT01666106AmgenOsteonecrosis of the Jaw (ONJ) Case Registry

Osteonecrosis of the Jaw (ONJ) Case Registry

Start: Oct 2012Est. completion: Dec 2020327 patients
N/ACompleted
NCT01130389Oregon TherapeuticsCONDOR Study of Osteonecrosis of the Jaws (TMJ)

CONDOR Study of Osteonecrosis of the Jaws (TMJ)

Start: Jan 2007Est. completion: Sep 2008309 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.